Carlyle Group Inc. - Q3 2023 holdings

$2.31 Billion is the total value of Carlyle Group Inc.'s 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .

 Value Shares↓ Weighting
 Quidelortho Corp$910,091,766
-11.9%
12,460,1830.0%39.47%
+7.3%
MKSI  MKS Instrs Inc$301,395,628
-19.9%
3,482,7320.0%13.07%
-2.5%
VTRU  Vitru Ltd$109,875,425
+9.7%
6,246,4710.0%4.77%
+33.6%
GDS  GDS Hldgs Ltdsponsored ads$44,595,237
-0.4%
4,072,6240.0%1.93%
+21.3%
VRNA  Verona Pharma Plcsponsored ads$40,008,100
-22.9%
2,457,5000.0%1.74%
-6.1%
PHAT  Phathom Pharmaceuticals Inc$36,191,963
-27.7%
3,496,8080.0%1.57%
-12.0%
 Hillevax Inc$24,690,867
-21.7%
1,838,4860.0%1.07%
-4.6%
RPHM  Reneo Pharmaceuticals Inc$20,539,063
+16.2%
2,698,9570.0%0.89%
+41.4%
SMHI  Seacor Marine Hldgs Inc$18,240,596
+21.4%
1,314,1640.0%0.79%
+47.9%
INVH  Invitation Homes Inc$15,131,975
-7.9%
477,5000.0%0.66%
+12.1%
CUBE  CubeSmart$8,407,665
-14.6%
220,5000.0%0.36%
+4.0%
SPRB  Spruce Biosciences Inc$6,459,235
+3.7%
2,896,5180.0%0.28%
+26.1%
 Jasper Therapeutics Inc$6,054,467
-48.8%
8,761,8910.0%0.26%
-37.5%
EM  Smart Sh Global Ltdads$3,634,594
-22.5%
4,810,2090.0%0.16%
-5.4%
ACET  Adicet Bio Inc$2,876,924
-43.8%
2,115,3850.0%0.12%
-31.3%
 Effector Therapeutics Inc$2,868,676
-27.5%
4,822,1140.0%0.12%
-12.1%
NCNA  Nucana Plcsponsored adr$1,966,666
-24.4%
3,333,3330.0%0.08%
-8.6%
 Meta Data Limitedsponsored ads$325,656
-3.2%
314,4000.0%0.01%
+16.7%
 Exicure Inc$199,962
-45.8%
281,6360.0%0.01%
-30.8%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-03
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Wesco Aircraft Hldgs Inc28Q4 201916.8%
Seacor Marine Hldgs Inc22Q3 20231.1%
Enviva Partners LP21Q2 202031.5%
Enduro Rty Tr21Q1 20182.8%
USA Compression Partners LP20Q2 201828.5%
Pattern Energy Group Inc20Q3 201816.2%
Concord Med Svcs Hldgs Ltd19Q3 20171.1%
Superior Energy Svcs Inc19Q3 20170.7%
Cobalt Intl Energy Inc17Q1 201711.0%
Sequential Brnds Group Inc N17Q1 20201.7%

View Carlyle Group Inc.'s complete holdings history.

Latest significant ownerships (13-D/G)
Carlyle Group Inc. Q3 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Complete Solaria, Inc.September 22, 20232,745,8795.7%
Carlyle Credit Income FundSeptember 14, 20234,785,62841.0%
eFFECTOR Therapeutics, Inc.August 18, 20234,829,8917.8%
Vera Therapeutics, Inc.August 02, 20231,872,7644.2%
Reneo Pharmaceuticals, Inc.May 09, 20232,730,4578.2%
EXICURE, INC.April 13, 2023287,1373.4%
SPRUCE BIOSCIENCES, INC.February 23, 20233,734,5189.2%
Vaxcyte, Inc.February 10, 20232,070,7242.6%
NuCana plcAugust 11, 20223,353,1346.4%
QuidelOrtho CorpJune 06, 202212,460,18318.6%

View Carlyle Group Inc.'s complete significant-ownership history.

Latest filings
TypeFiled
SC 13D/A2024-05-13
10-Q2024-05-07
13F-HR2024-05-03
42024-05-03
42024-05-03
42024-05-03
42024-05-03
42024-05-03
42024-05-03
42024-05-03

View Carlyle Group Inc.'s complete filings history.

Compare quarters

Export Carlyle Group Inc.'s holdings